The resurgence of haploidentical donor transplantation over the past decade is a major advance in the field of hematopoietic cell transplantation (HCT). Several platforms have been described, such as ex vivo T-cell depletion techniques with positive-CD34+ selection, 'mega-dose' of purified CD34+ cells, or selective depletion of T-cells, and T-cell replete approaches that include use of intensified immune suppression or post-transplant highdose cyclophosphamide. [1] [2] [3] It is safe to say that haploidentical transplantation has become a well-accepted alternative donor source, with several studies reporting survival comparable to umbilical cord blood and matched unrelated donors. [4] [5] [6] [7] [8] Ongoing clinical trials such as the BMT CTN 1101 (double cord versus haplo) will further clarify where haploidentical donors factor into the donor selection process.
Yan et al., 9 in this issue of Bone Marrow Transplantation, present their experience with T-cell replete haploidentical transplantation using intensified GvHD prophylaxis and compare the incidence and causes of mortality with HLA-identical sibling donor HCT recipients. Both groups received myeloablative conditioning. In their large cohort of 1411 patients, they show that the cumulative incidence of overall mortality and transplant-related mortality (TRM) was higher after haploidentical HCT, but there was no difference in the incidence of relapse-related mortality. TRM in haploidentical HCT recipients was primarily driven by a higher risk of infection-related mortality that mainly occurred in the first 3-6 months posttransplant. This is not surprising, given that the haploidentical donor cohort received more intensive immune suppression, including anti-thymocyte globulin. Intensifying pharmacologic GvHD prophylaxis and use of in vivo T-cell depletion is associated with slow and prolonged T-cell recovery, delay in immune reconstitution and its associated risks of infections. 1, 10 Indeed, the authors have previously reported a higher incidence of invasive fungal disease, EBV reactivation and post-transplant lymphoproliferative disease, and CMV disease in haploidentical transplant recipients. 11, 12 Previous studies from their group have also demonstrated a higher incidence of grade 1-4 acute GvHD in haploidentical HCT recipients, which would have resulted in more patients receiving post-transplant immune suppression compared with HLA-identical sibling donor recipients. However, mortality rates due to GvHD were low in both cohorts. Relapse was the most common cause of death in HLA-identical sibling donor HCT recipients and was second most common cause after infections in haploidentical donor transplant recipients. In subgroup analyses, they showed no difference in overall mortality or TRM in acute leukemia patients by donor source, but reported a higher incidence of both outcomes in patients with myelodysplastic syndromes who received haploidentical transplantation. The authors attribute this finding to longer duration of neutropenia in patients with myelodysplastic syndromes, although it is not clear why these two donor sources would have any differences in neutrophil engraftment and the number of patients with this particular disease was small.
Some limitations of their retrospective cohort analysis have to be considered. The cohort ranges from 2000 to 2011, and presumably, supportive care practices would have improved over that time period. The authors do not present details on the types of infections contributing to mortality in their cohort. The results of this study are specific to their technique for haploidentical transplantation and do not apply to other approaches, such as the T-cell replete platform that includes posttransplant cyclophosphamide and is more frequently used in the United States and Europe. Recent studies have shown comparable probabilities of overall survival among myeloablative and reduced-intensity haploidentical HCT with post-transplant cyclophosphamide as GvHD prophylaxis and matched unrelated donor HCT. 4, 5 However, there are limited data on the outcomes of posttransplant cyclophosphamide based haploidentical versus HLA-identical sibling donor transplantation. In a single center study, Bashey et al. 4 reported 2-year overall survival rates of 57% for haploidentical, 59% for matched unrelated donor (P = NS versus haploidentical), and 72% for HLA-identical sibling donor (P = 0.02 versus haploidentical) transplantation. However, there were no differences in the cumulative incidences of relapse and non-relapse mortality. In another single institution study, albeit with a small number of patients, survival after haploidentical HCT using post-transplant cyclophosphamide was reported to be similar to survival of patients receiving matched related donor grafts. 13 Taken together, haploidentical donors can be considered as an acceptable alternative donor choice for patients who need HCT. At least in the intensified GvHD prophylaxis haploidentical HCT approach, where in vivo T-cell depletion is frequently incorporated within the conditioning regimen, special attention to infection risk is needed. Based on experience with other transplantation modalities, it is reasonable to consider more aggressive than usual methods to monitor for and prevent infections while evidence for best practices in this setting accumulates (for example, monitoring and preemptive treatment of EBV reactivation and CMV prophylaxis using ganciclovir). 1 The plethora of haploidentical transplant platforms show great promise and several approaches have been reported to have survival comparable to matched unrelated and umbilical cord blood transplantation, but HLA-identical sibling should continue to be the optimal donor choice, if the patient has that option. Although the nuances of donor choices, haploidentical
